Response assessment
| . | After cycle 2 scan, no. (%) . | After cycle 6 scan, no. (%) . |
|---|---|---|
| CT (n = 81) | ||
| CR | 12 (15) | 27 (33) |
| CRu | 9 (11) | 18 (22) |
| PR | 49 (60) | 32 (40) |
| SD | 8 (10) | 2 (2) |
| NA | 3 (4) | 2 (2) |
| CR/Cru | 21 (26) | 45 (55) |
| ORR | 70 (86) | 77 (95) |
| PET | ||
| PET-positive | 15 (22) | 8 (11) |
| PET-negative | 54 (78) | 61 (88)* |
| . | After cycle 2 scan, no. (%) . | After cycle 6 scan, no. (%) . |
|---|---|---|
| CT (n = 81) | ||
| CR | 12 (15) | 27 (33) |
| CRu | 9 (11) | 18 (22) |
| PR | 49 (60) | 32 (40) |
| SD | 8 (10) | 2 (2) |
| NA | 3 (4) | 2 (2) |
| CR/Cru | 21 (26) | 45 (55) |
| ORR | 70 (86) | 77 (95) |
| PET | ||
| PET-positive | 15 (22) | 8 (11) |
| PET-negative | 54 (78) | 61 (88)* |
Patients who were PET-negative after 2 cycles and completed treatment and did not have a posttreatment PET scan were considered PET-negative after treatment if the posttreatment CT scan did not show progression.